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Available online xxxxIntroduction: Neurotransmitters are chemical messengers that enable communication between the neurons in
the synaptic cleft. Inborn errors of neurotransmitter biosynthesis, breakdown and transport are a group of very
rare neurometabolic diseases resulting in neurological impairment at any age from newborn to adulthood.
Methods and results: The International Working Group on Neurotransmitter related Disorders (iNTD) is the ﬁrst
international network focusing on the study of primary and secondary neurotransmitter disorders. It was
founded with the aim to foster exchange and improve knowledge in the ﬁeld of these rare diseases. The newly
established iNTD patient registry for neurotransmitter related diseases collects longitudinal data on the natural
disease course, approach to diagnosis, therapeutic strategies, and quality of life of affected patients. The registry
forms the evidence base for the development of consensus guidelines for patients with neurotransmitter related
disorders.
Conclusion: The iNTD network and registry will improve knowledge and strengthen research capacities in the
ﬁeld of inborn neurotransmitter disorders. The evidence-based guidelines will facilitate standardized diagnostic
procedures and treatment approaches.
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Neurotransmitters are a group of chemical messengers that enable
communication between the neurons in the synaptic cleft. With regard
to chemical properties, neurotransmitters can be grouped into amino
acids (including glutamate, glycine, serine and gamma aminobutyric
acid), peptides, purines, andmonoamines or biogenic amines (including
acetylcholine, epinephrine, norepinephrine, dopamine and serotonin).
Most neurotransmitters have either excitatory or inhibitory effects,
but only a few can exert both depending upon the type of receptors
that are present [13]. After biosynthesis neurotransmitters are stored
within synaptic vesicles and secreted in response to the appropriate
nerve impulse [13]. Peptides have higher molecular weight than bio-
genic amines and amino acids, and are produced and released by
neurons through the regulated secretory route. Interestingly, many
peptides exhibit neurotransmitter activity as well as possess hormonal
function.
Inborn errors of neurotransmitter biosynthesis, breakdown or trans-
port are a group of very rare neurometabolic diseases. The incidence of
the combined neurotransmitter diseases can only be estimated, but so
far around 1500 patients have been published worldwide [3,12,19,21,
28]. Clinical symptoms can appear at any age from newborn to adult-
hood. In the following the different groups of neurotransmitter disor-
ders and their main features are described:
Disorders of monoamines and tetrahydrobiopterin metabolism.
Tetrahydrobiopterin (BH4) is known to be the natural cofactor for
phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), and tryp-
tophan hydroxylase (TPH) as well as all three isoforms of nitric oxide
synthase (NOS) [27]. The BH4 dependent enzymes TH and TPH are to-
gether with the aromatic amino acid decarboxylase (AADC) the key en-
zymes in the biosynthesis of the neurotransmitters dopamine and
serotonin [1]. Accordingly, disorders of BH4 metabolism result in deﬁ-
ciency of biogenic amines. In addition to enzyme deﬁciencies, two
transporter defects are known to cause disorders of biogenic amineme-
tabolism [16,23]. The relevant enzymes and transporters are listed in
Table 1. The clinical presentation is determined by the type and severityTable 1
Overview on inborn errors of neurotransmitter metabolism included in the iNTD patient
registry, including acronym and OMIM number (Online Mendelian Inheritance in Man).
Disease name Acronym
Gene
name OMIM#
Aromatic L-amino acid decarboxylase
deﬁciency
AADCD DDC #608643
Tyrosine hydroxylase deﬁciency THD TH #191290
Dopamine β-hydroxylase deﬁciency DßHD DßH #223360
Monoamine oxidase A deﬁciency MOAAD MAO-A # 309850
Dopamine transporter deﬁciency DATD SLC6A3 #126455
Vesicular monoamine transporter deﬁciency VMATD SLC18A2 #193001
Autosomal recessive GTP-cyclohydrolase
deﬁciency
ARGTPCHD GCH1 #233910
Autosomal dominant GTP-cyclohydrolase
deﬁciency
ADGTPCHD GCH1 #600225
6-Pyruvoyl-tetrahydropterin synthase
deﬁciency
PTPSD PTS #261640
Dihydropteridine reductase deﬁciency DHPRD QDPR #261630
Sepiapterin reductase deﬁciency SRD SPR #182125
Folate receptor alpha deﬁciency FOLR1D FOLR1 # 613068
Dihydrofolate reductase deﬁciency DHFRD DHFR # 613839
3-Phosphoglycerat dehydrogenase
deﬁciency
3-PGDHD PHGDH #606879
3-Phosphoserine phosphatase deﬁciency 3-PSPD PSPH #172480
Phosphoserine aminotransferase deﬁciency PSATD PSAT1 #610936
Nonketotic hyperglycinemia NKH AMT
GLDC
GCSH
T#238310
P#238300
H#238330
GABA-transaminase deﬁciency GABATD ABAT #137150
Succinate semialdehyde dehydroxylase
deﬁciency
SSADHD ALDH5A1 #271980of the underlying disorder [18] and ranges from intermittent focal dys-
tonia and dystonia-parkinsonism to severe, lethal infantile encephalop-
athies. In adulthood these diseases may cause behavioral and mood
disorders [11,20,25]. Patients with disorders of BH4 metabolism can
with two exceptions be identiﬁed by detection of hyperphenylalanin-
emia on newborn screening (PKU), thereby allowing early diagnosis
and initiation of treatment in asymptomatic individuals.
1.1. Folates
Folates play an essential role in central one-carbon methyl transfer
reactions, mediating several biological processes including synthesis of
neurotransmitters. 5-MTHF is the widely distributed form in the blood-
stream. The autosomal recessive inherited folate receptor alpha
(FOLR1) deﬁciency leads to impaired transport of folate to the CNS
resulting in psychomotor decline, progressive movement disturbance,
white matter disease, and epilepsy [5,24]. Patients with dihydrofolate
reductase deﬁciency (DHFR) present with megaloblastic anemia, cere-
bral folate deﬁciency and a variety of neurological manifestations,
which respond at least partly to treatment with folinic acid [6].
1.2. Disorders of GABA metabolism
Two disorders of GABA catabolism are known: Succinic semialde-
hyde dehydrogenase (SSADH) and GABA-transaminase deﬁciency.
Most patients with SSADH deﬁciency develop symptoms in the ﬁrst
2 years of life and present with prominent deﬁcits in expressive
language, motor delay, hypotonia, non-progressive ataxia, epilepsy
and neuropsychiatric symptoms [10,22]. Two families with GABA-
transaminase deﬁciency have been reported displaying developmental
delay and hypotonia in early childhood and severe expressive language
impairment and obsessive-compulsive disorder in adolescence and
adulthood as well as ataxia and hyporeﬂexia [14,26].
1.3. Disorders of serine metabolism
Defects of serine metabolism encompass phosphoglycerate dehy-
drogenase deﬁciency, phosphoserine aminotransferase deﬁciency, and
3-phosphoserine phosphatase deﬁciency. Patients with phosphoglycer-
ate dehydrogenase or phosphoserine aminotransferase manifest with
severe intellectual disability, spastic tetraparesis, severe microcephaly
and epilepsy [8]. A deﬁciency of 3-phosphoserine phosphatase was
identiﬁed in one patient with moderate intellectual disability who also
had Williams's syndrome [15] and in another patient with intrauterine
growth restriction, intellectual disability, childhood onset epilepsy, and
borderline microcephaly who developed progressive lower extremity
hypertonia, axonal neuropathy, and hand contractures in adulthood [4].
1.4. Disorders of glycine breakdown
A deﬁciency of the activity of the glycine cleavage enzyme system
leads to nonketotic hyperglycinemia (NKH) due to an accumulation of
glycine in tissues and the central nervous system. Based on the amount
of residual activity resulting from the particular mutation, clinical pre-
sentation of NKH ranges from severe neonatal hypotonia, failure to
thrive and burst suppression pattern on EEG in the severe form, to
mild mental retardation, learning disabilities or even normal intelli-
gence in the mild from [7,12].
All neurotransmitter related disorders are rare, and consequently,
patients are scattered around the world and frequently do not have ac-
cess to medical care at centers of expertise. Furthermore, evidence base
of current diagnostic and therapeutic approaches is extremely limited
and current diagnostic and treatment strategies vary enormously
between centers, resulting in sub-optimal care for individual
patients. It can be expected that these inequalities have a negative
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other rare diseases [2,17].
The major aims of the International Working Group on Neurotrans-
mitter related Disorders (iNTD) are to establish the ﬁrst network and
patient registry for neurotransmitter related disorders. The patient reg-
istry will enable detailed analysis of the natural courses of the diseases,
the diagnostic approaches and the current therapy strategies as well as
the quality of life of the affected patients and possible genotype/
phenotype-correlations. Besides expanding knowledge about these dis-
eases, iNTD will enable the development of the ﬁrst evidence-based
consensus guidelines for patients with various neurotransmitter related
disorders.
This paper describes the establishment of iNTD and major achieve-
ments within the ﬁrst 2 years of the project.2. Methods
2.1. The iNTD network
In 2013 the initiative “International Working Group on Neurotrans-
mitter Related Disorders (iNTD)”was founded by threemedical experts
from the University Hospital Heidelberg (Germany), the Hospital Sant
Joan de Déu in Barcelona (Spain) and the Great Ormond Street Hospital
in London (United Kingdom) with the aim to foster scientiﬁc and clini-
cal networking on an international level and, ultimately, to promote
health care for patients with neurotransmitter related disorders. Since
then the network has continued to grow and today iNTD consists of
43 project partners from 24 countries worldwide (Fig. 1 and supple-
ment 1). iNTD launched a network website (www.intd-online.org),
where network information and activities are announced. Furthermore,
the website provides disease related information for families and care-
takers as well as health professionals. The steering committee consists
of Thomas Opladen (University Hospital Heidelberg), Àngels Garcia-
Cazorla (Hospital Sant Joan de Déu Barcelona) and Manju Kurian
(Great Ormond Street Hospital London). The steering committee has
the overall responsibility to ensure satisfactory progress of the network.
It speciﬁes and deﬁnes the organization, management, responsibilities
and tasks of the network. All iNTD networkmembers that are contribut-
ing to the registry have signed a consortium agreement.AADC (24) 
25% 
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MAOA (1) 
1% 
ARGTPCH (4)
4% ADGTPCH (12) 
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Fig. 1. Total number, frequency and distribution of neurotransmitter deﬁciencies in the
iNTD patient registry.2.2. The patient registry
Within one working group iNTD set up the ﬁrst international, longi-
tudinal patient registry for neurotransmitter related disorders. The pa-
tient registry is web-based and password-protected (https://intd-
registry.org). It was approved by the local ethics committee of the Uni-
versity Hospital Heidelberg (coordinating center, application number S-
471/2014) on 22th December 2014. The data are managed on a secure
server, hosted by University Hospital Heidelberg, the site responsible
for data storage and processing. The previously existing, stand-alone
registries for BH4 and AADC deﬁciencies, BIODEF and JAKE, established
and hosted at the University Children's Hospital in Zürich, Switzerland
by Prof. Nenad Blau, have ceased collection of new patient data. To pre-
serve the highly valuable historical data contained in BIODEF and JAKE,
the iNTD registry will collaborate with both registries to transfer
existing data into the iNTD registry after obtaining informed consent
of the respective patients, parents or legal representatives.
Patients' data is collected after written informed consent is obtained
by physicians at each participating iNTD center. After a baseline visit,
longitudinal follow-up visits are performed annually. Initially only dis-
orders of biogenic amine metabolism, BH4 deﬁciencies and cerebral fo-
late deﬁciencies were included. In January 2016 the registry was
extended to amino acid neurotransmitter diseases including the serine
synthesis deﬁciencies, disorders of glycine metabolism and GABA relat-
ed disorders (listed in Table 1). At the same time we also began to reg-
ister patients with abnormal CSF results suggesting a neurotransmitter
disorder but without known diagnosis, for further research purposes.
3. Results
iNTD aims for worldwide coverage. At the time of publication, the
iNTD network included 43 partners from 3 continents and 24 different
countries (for details see list of iNTD network partners in the supple-
ment). At present, 21 clinical partners have met all necessary legal re-
quirements and are contributing data to the registry. The approval of
further study centers is in process and will follow. Since data collection
began in January 2015, the number of patients is steadily growing. As of
30 June 2015, 95 patients with a conﬁrmed diagnosis of neurotransmit-
ter related disorders have been registered. In total 95 baseline visits and
33 follow up visits have been documented in the registry so far.
Patients with AADC deﬁciency are so far the most frequent popula-
tion in the registry (n = 24, 25%), followed by PTPS deﬁciency (n =
22, 23%) and autosomal dominant GTPCH deﬁciency (n= 12, 13%; de-
tails in Fig. 1). The predominance of AADC deﬁciency is partly explained
by the support of the AADC parent organization (AADC Research Trust;
www.aadcresearch.org) which promoted the study within their mem-
bership. There are few patients with disorders of amino acid neuro-
transmitter metabolism as a result of their very recent inclusion in the
registry. At present there are no patients with folate disorders included.
The median age of patients in the database is 10.3 years (range: 3
months to 42.5 years). Of note, 25 patients (26.3%) in the registry are
older than 16 years (Table 2). It is obvious that with a growing adult co-
hort, newmedical and social care aspects including behavioral aswell as
psychological problems, puberty and integration into the social life and
work systems will arise. First epidemiological results conﬁrm the
discrepancy between age of symptom onset and age at diagnosis for
some disorders (Fig. 2).
3.1. Guideline development
In neurotransmitter related disorders clinical symptoms can be non-
speciﬁc and diagnosis is often delayed depending signiﬁcantly on the
personal experience of the treating physician. As a consequence, pa-
tients and their parents often traverse a stressful odyssey from doctor
to doctor with frequent misdiagnoses, such as cerebral palsy, myasthe-
nia gravis or seizure disorders [9,19] before the correct diagnosis is
Table 2
Current number, gender distribution, age range, age at ﬁrst symptoms and age at diagnosis of 95 patients included in the iNTD registry. m = male; f = female.
Disease name Number and gender of patients Age range Age range at ﬁrst symptoms (median) Age range at diagnosis (median)
AADC deﬁciency 24 (5 m/19f) 8.0 months–36.0 years 1st month of life–5.0 months
(2.5 months)
4.9 months–32.0 years
(9.8 months)
TH deﬁciency 11 (3 m/8f) 3.0 years–35.6 years 1st month of life–5.0 months
(3.0 months)
5.5 months–30.0 years
(2.8 years)
MAOA deﬁciency 1 (1 m/0f) 4.5 years 6.0 months 21.6 months
ARGTPCH deﬁciency 4 (4 m/0f) 4.0 years–32.7 years 1st month of life–48.0 years
(13.8 months)
5.9 months–6.0 years
(1.4 years)
ADGTPCH deﬁciency 12 (3 m/9f) 3.8 years–41.8 years 6.0 months–9.0 years
(44.1 months)
1.5 years–36.0 years
(7.0 years)
PTPS deﬁciency 22 (9 m/13f) 2.0 years–42.5 years 1st month of life–1.5 years
(3.8 months)
0.1 months–7.8 years
(1.0 month)
DHPR deﬁciency 11 (5 m/6f) 3.0 months–26.3 years 1st month of life–2.0 years
(8.0 months)
0.1 months–2.8 years
(6.9 month)
SR deﬁciency 2 (1 m/1f) 3.7 years–8.6 years 6.0 months
(6.0 months)
6.9 months−.6 years
(3.6 years)
3-PGDH deﬁciency 1 (1 m/0f) 8.9 years 1st month of life 4.9 months
NKH 4 (2 m/2f) 5.2 years–17.9 years 1st month of life–3.0 years
(9.8 months)
0.1 months–5.0 years
(2.4 months)
SSADH deﬁciency 4 (2 m/2f) 1.2 years–10.5 years 2.0 months–.5 years
(10.3 months)
2.9 years–10.8 years
(4.0 years)
Total 95 (36 m/59f) 3.0 months–42.5 years 1st month of life–9.0 years
(3.0 months)
0.1 months–36.0 years
(1.1 years)
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ible worsening of the patient's condition and result in signiﬁcant costs
for the health care system. Since evidence-based guidelines for diagno-
sis and treatment do not exist for any of these disorders, one working
group of iNTD is focused upon the development of evidence based
guidelines for the most frequent neurotransmitter disorders. The evi-
dence base will be derived from a systematic literature search and
review, in addition to data from the patient registry. Relevant publica-
tions will be identiﬁed and evaluated using a standardized procedure
in analogy to the methodology of SIGN (Scottish Intercollegiate Guide-
line Network; www.sign.ac.uk) and GRADE (Grading of Recommenda-
tions Assessment, Development and Evaluation Working Group). In
the following, evidence-based recommendations will be formulated
for diagnostic procedures, therapeutic strategies, and follow-up moni-
toring. The guidelines will be published in peer reviewed journals.
The ﬁrst guidelines developed by iNTD were for the diagnosis and
treatment of AADC deﬁciency (Wassenberg T, Orphanet J Rare Dis,
2016, in press). The guideline working group consisted of 13 child neu-
rologists, 5 biochemists and 1 research project manager from several
European countries, the USA and Taiwan. All group members are afﬁli-
ated with iNTD and are experienced in the diagnosis and treatment of
AADC deﬁciency. Furthermore, a representative of the European AADC
parental organization participated in guideline development). The de-
velopment of evidence based guidelines for inborn errors of BH4 disor-
ders will follow in near future as the next iNTD guideline.
4. Discussion
In developed countries, where infant mortality caused by infectious
diseases is low, research on rare diseases has a very high priority as stat-
ed in the European Commission's Communication on Rare Diseases:
“Coordination projects aimed at an optimal use of the limited resources
dedicated to research on rare diseases should be encouraged” (Source:
Communication from the commission to the European Parliament, the
Council, the European Economic and Social Committee of the Regions,
11. November 2008).
Because inherited neurotransmitter related disorders are very rare,
signiﬁcant progress can only be achieved by transnational efforts. For
that purpose, an international network and registry for rare neurotrans-
mitter related disorders are indispensable to improve the knowledge
base, develop international consensus care guidelines, and foster net-
working on international level and, ultimately, to promote health carefor patients with neurotransmitter related disorders. Additionally,
since many of these disorders are amenable to treatment, promoting
awareness and knowledge among the medical community is a matter
of great importance.
In the last 2 years, iNTD has established the ﬁrst worldwide network
of experts for neurotransmitter related disorders. The iNTD network
provides a platform for clinicians and scientists to exchange expertise
and to improve international collaborations regarding these rare neuro-
transmitter related diseases. Currently iNTD includes 43 metabolic cen-
ters from 24 countries worldwide and is open for collaboration with
additional stakeholders. iNTD seeks to build partnerships between sci-
entists and non-governmental parent organizations with longstanding
basic research, diagnostic and clinical activities. The consortium aims
to mobilize a critical mass of expertise and patient numbers to enable
rapid translation of basic research into clinical studies at the patient's
bedside.
The iNTD registry study is the ﬁrst detailed longitudinal study in the
ﬁeld of neurotransmitter disorders. To enable systematic and standard-
ized collection of data, all patient data entered into the registry are sur-
veyed by medical doctors. The successful initiation of the registry in
January 2015 and the constantly growing number of registered patients
will enable detailed clinical phenotyping of the diseases for the ﬁrst
time, and interdisciplinary analysis of the natural history, diagnostic ap-
proaches and current treatment strategies, genotype/phenotype corre-
lation, as well as the quality of life of affected patients.
4.1. Outlook
Within the last 2 years iNTD has developed a stable framework for
exchange in clinical and scientiﬁc research. In future iNTD aims to fur-
ther improve the awareness and knowledge on rare neurotransmitter
related disorders by providing clinical and scientiﬁc information to
patients and health care professionals. The iNTD registry seeks the in-
clusion of more than 250 patients in the registry by extending coopera-
tion with other expert centers. The long term focus will be on the
evaluation of disease natural history, speciﬁcally in the context of up-
coming new treatment options. As one example Dr. Toni Pearson
(Washington University in St Louis, USA) developed a highly detailed
parent questionnaire for patientswith AADC deﬁciencywhich evaluates
the natural course, in the context of the upcoming gene therapy trials
for AADC deﬁciency in the USA and England. Thanks to the modular IT
system the extension of the iNTD patient registry and the inclusion of
Fig. 2.Age atﬁrst symptoms versus age at diagnosis in 95 patientswith different neurotransmitter disorders (Boxplotwithmedian, quartiles, outliers (caseswith values between 1.5 and 3
box lengths from the upper or lower edge of the interquartile range) and extremes (cases with values more than 3 box lengths from the upper or lower edge of the interquartile range).
65T. Opladen et al. / Molecular Genetics and Metabolism Reports 9 (2016) 61–66any newly described neurotransmitter related disorder are possible.
Hereby a standardized clinical and biochemical characterization of the
new disorder and a direct comparisons with known disorders will be
easily possible.
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